NEW
YORK, July 28, 2023 /PRNewswire/ -- Jakubowitz
Law announces that a securities fraud class action
lawsuit has commenced on behalf of shareholders of ImmunityBio,
Inc. (NASDAQ: IBRX).
To receive updates on the lawsuit, fill out the
form:
https://claimyourloss.com/securities/immunitybio-class-action-loss-submission-form/?id=42673&from=4
The lawsuit seeks to recover losses for shareholders who
purchased ImmunityBio between May 23,
2022 and May 10, 2023.
Shareholders interested in acting as a lead plaintiff
representing the class of wronged shareholders have until
August 29, 2023 to petition
the court. Your ability to share in any recovery doesn't require
that you serve as a lead plaintiff.
According to a filed complaint, ImmunityBio, Inc. issued
materially false and/or misleading statements and/or failed to
disclose that: (i) ImmunityBio conducted insufficient due diligence
to discover, or else did discover and ignored, Good Manufacturing
Practice ("GMP") deficiencies at its third-party contract
manufacturing organizations ("CMOs") for the antibody cytokine
fusion protein N-803, commercially referred to as "Anktiva"; (ii)
one or more of the Company's third-party CMOs for Anktiva did in
fact suffer from GMP deficiencies; (iii) the foregoing deficiencies
was likely to cause the FDA to reject the Anktiva Biologics License
Application ("BLA") in its present form; (iv) accordingly, the
Company overstated the regulatory approval prospects for the
Anktiva BLA; and (v) as a result, the Company's public statements
were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for
shareholders who have been the victim of securities
fraud. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/ibrx-shareholder-alert-jakubowitz-law-reminds-immunitybio-shareholders-of-a-lead-plaintiff-deadline-of-august-29-2023-301887828.html
SOURCE Jakubowitz Law